Feng Yu / Shutterstock.com
Sweden-based pharmaceutical research company BioInvent International has been granted additional patent protection for its BI-505 immune oncology programme for myeloma.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
BioInvent International, myeloma, ICAM-1, cancer, Michael Oredsson, antibody cells, BI-505, patent